Drug combination before surgery for early-stage lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs — a targeted chemotherapy and an immunotherapy — given before surgery for people with early-stage but locally advanced lung cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have been diagnosed with non-small cell lung cancer that can be removed with surgery (Stage II to IIIB).
- Your tumor does not have changes in the EGFR or ALK genes.
- You have not had any prior treatment for this lung cancer, such as chemotherapy, radiation, or surgery.
- You are fit enough to have surgery and your organs (like heart, liver, and kidneys) are working well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests a combination of two drugs (sacituzumab tirumotecan and tagitanlimab) given before surgery for people with a specific type of lung cancer that is PD-L1 positive and can be removed. The goal is to see if this treatment helps shrink the tumor and improves outcomes after surgery.
This trial tests whether giving two immunotherapy drugs before surgery can help shrink non-small cell lung cancer and improve treatment success. The drugs are toripalimab and sacituzumab tirumotecan, which are given as intravenous infusions.
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
This study tests whether giving a combination of two medications before surgery can help shrink oral cancer tumors and improve treatment outcomes. The medications are a targeted therapy (called TROP-2 ADC) and an immunotherapy (called toripalimab), and you would receive them before your planned surgery.
This study tests a combination of two drugs for stage III lung cancer that can't be removed by surgery. One drug is an antibody-drug conjugate that targets cancer cells, and the other is an immunotherapy that helps your immune system fight cancer. The goal is to see if this combo shrinks or controls the tumor.
Hear when a new NSCLC (Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.